Nutra Pharma Corp (NPHC) Research & Development (2010 - 2012)

Nutra Pharma has disclosed Research & Development across 3 years of filings, most recently posting $485.0 for Q2 2012.

• In Q2 2012, Research & Development fell 99.21% year-over-year to $485.0; the TTM figure through Dec 2012 stood at $3046.0 (down 96.65% YoY), while the FY2012 annual figure was $3046.0, down 96.65% from the prior year.
• Research & Development came in at $485.0 for Q2 2012 at Nutra Pharma, down from $2561.0 in the prior quarter.
• In the past five years, Research & Development ranged from a high of $102435.0 in Q2 2010 to a low of $485.0 in Q2 2012.
• Average Research & Development over 3 years is $25653.8, with a median of $16985.0 recorded in 2010.
• Year-over-year, Research & Development retreated 1.7% in 2011 and sank 99.21% in 2012.
• Over 3 years, Research & Development stood at $16985.0 in 2010, then tumbled by 78.65% to $3626.0 in 2011, then slumped by 86.62% to $485.0 in 2012.
• Per Business Quant data, the three most recent Research & Development figures were $485.0 in Q2 2012, $2561.0 in Q1 2012, and $3626.0 in Q4 2011.